Thomas Folinsbee
Director/Board Member at CASI PHARMACEUTICALS, INC.
Thomas Folinsbee active positions
| Companies | Position | Start | End |
|---|---|---|---|
| CASI PHARMACEUTICALS, INC. | Director/Board Member | 20/03/2023 | - |
| Independent Dir/Board Member | 20/03/2023 | - | |
| Shanghai Alebund Pharmaceuticals Ltd. | Corporate Officer/Principal | 31/12/2018 | - |
Career history of Thomas Folinsbee
Former positions of Thomas Folinsbee
| Companies | Position | Start | End |
|---|---|---|---|
Bison Capital Acquisition Corp.
 Bison Capital Acquisition Corp. Financial ConglomeratesFinance Bison Capital Acquisition Corp. is currently a blank check company, which primarily engages in the acquisition, and engagement in share exchange, share reconstruction and amalgamation with, contractual control arrangement with, purchasing all or substantially all of the assets of an entity. It also plans on engaging in any other similar business combination with one or more entities. The company is headquartered in Beijing, China. | Director/Board Member | 30/05/2017 | 31/12/2018 |
| Independent Dir/Board Member | 30/05/2017 | 31/12/2018 | |
| 3SBIO INC. | Corporate Officer/Principal | 31/12/2008 | 31/12/2018 |
| Hisanaga Seisakusho Co. Ltd. | Director/Board Member | 31/12/2010 | 31/12/2015 |
| SUMT HEAL | Director/Board Member | - | - |
| Independent Dir/Board Member | - | - | |
| XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | Director/Board Member | 31/12/2018 | - |
| Independent Dir/Board Member | 31/12/2018 | - |
Training of Thomas Folinsbee
| McGill University | Undergraduate Degree |
Statistics
International
| Cayman Islands | 4 |
| China | 4 |
| Canada | 2 |
Operational
| Director/Board Member | 5 |
| Independent Dir/Board Member | 4 |
| Corporate Officer/Principal | 2 |
Sectoral
| Health Technology | 4 |
| Finance | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| 3SBIO INC. | Health Technology |
| CASI PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
| Hisanaga Seisakusho Co. Ltd. | |
Bison Capital Acquisition Corp.
Bison Capital Acquisition Corp. Financial ConglomeratesFinance Bison Capital Acquisition Corp. is currently a blank check company, which primarily engages in the acquisition, and engagement in share exchange, share reconstruction and amalgamation with, contractual control arrangement with, purchasing all or substantially all of the assets of an entity. It also plans on engaging in any other similar business combination with one or more entities. The company is headquartered in Beijing, China. | Finance |
Xynomic Pharmaceuticals Holdings, Inc.
 Xynomic Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. It engages in licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma and non-Hodgkin's lymphoma. The company was founded by Yinglin Mark Xu on October 7, 2016 and is headquartered in Shanghai, China. | Health Technology |
Summit Healthcare Acquisition Corp.
 Summit Healthcare Acquisition Corp. Financial ConglomeratesFinance Summit Healthcare Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The company was founded on December 22, 2020 and is headquartered in Hong Kong. | Finance |
| Shanghai Alebund Pharmaceuticals Ltd. |
- Stock Market
- Insiders
- Thomas Folinsbee
- Experience
